Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD).
Rancati F, Linney ID, Rizzi A, Delcanale M, Knight CK, Schmidt W, Pastore F, Riccardi B, Mileo V, Carnini C, Cesari N, Blackaby WP, Patacchini R, Carzaniga L. Rancati F, et al. Among authors: mileo v. Bioorg Med Chem Lett. 2021 Jun 1;41:127975. doi: 10.1016/j.bmcl.2021.127975. Epub 2021 Mar 19. Bioorg Med Chem Lett. 2021. PMID: 33753262
CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window.
Villetti G, Carnini C, Battipaglia L, Preynat L, Bolzoni PT, Bassani F, Caruso P, Bergamaschi M, Pisano AR, Puviani V, Stellari FF, Cenacchi V, Volta R, Bertacche V, Mileo V, Bagnacani V, Moretti E, Puccini P, Catinella S, Facchinetti F, Sala A, Civelli M. Villetti G, et al. Among authors: mileo v. J Pharmacol Exp Ther. 2015 Mar;352(3):568-78. doi: 10.1124/jpet.114.220558. Epub 2015 Jan 9. J Pharmacol Exp Ther. 2015. PMID: 25576073
Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases.
Carzaniga L, Linney ID, Rizzi A, Delcanale M, Schmidt W, Knight CK, Pastore F, Miglietta D, Carnini C, Cesari N, Riccardi B, Mileo V, Venturi L, Moretti E, Blackaby WP, Patacchini R, Accetta A, Biagetti M, Bassani F, Tondelli M, Murgo A, Battipaglia L, Villetti G, Puccini P, Catinella S, Civelli M, Rancati F. Carzaniga L, et al. Among authors: mileo v. J Med Chem. 2022 Aug 11;65(15):10233-10250. doi: 10.1021/acs.jmedchem.2c00609. Epub 2022 Jul 28. J Med Chem. 2022. PMID: 35901125
Designing Soluble PROTACs: Strategies and Preliminary Guidelines.
García Jiménez D, Rossi Sebastiano M, Vallaro M, Mileo V, Pizzirani D, Moretti E, Ermondi G, Caron G. García Jiménez D, et al. Among authors: mileo v. J Med Chem. 2022 Oct 13;65(19):12639-12649. doi: 10.1021/acs.jmedchem.2c00201. Epub 2022 Apr 25. J Med Chem. 2022. PMID: 35469399 Free PMC article.
Sample preparation strategy for the detection of steroid-like compounds using MALDI mass spectrometry imaging: pulmonary distribution of budesonide as a case study.
Zecchi R, Franceschi P, Tigli L, Amidani D, Catozzi C, Ricci F, Salomone F, Pieraccini G, Pioselli B, Mileo V. Zecchi R, et al. Among authors: mileo v. Anal Bioanal Chem. 2021 Jul;413(16):4363-4371. doi: 10.1007/s00216-021-03393-6. Epub 2021 May 17. Anal Bioanal Chem. 2021. PMID: 34002273 Free PMC article.
12 results